November 2026—Fixing a problem may start with identifying it, but naming is often only the starting pistol in a much longer race. The distance between recognizing the issues of iron deficiency and related anemia, and providing a diagnosis and treatment, can often stretch months to years. Improvements in the field have been more tortoise than hare. But the pace may be picking up. This fall, the American Society …
November 2026—The first broad set of recommendations for gender-diverse patient care, endorsed by the ADLM and published in July, spell out how to interpret routine testing in this population—and go far beyond. They cover not only laboratory medicine but also anatomic pathology and informatics. Gender-affirming hormone therapy affects a relatively small group of laboratory tests, and decades of research have shown the test results can be interpreted in accordance with the patient’s affirmed gender, with a few exceptions. Tiffany Thomas, PhD, coauthor of the guidance and assistant professor in the Department of Pathology and Cell Biology at Columbia University, uses a flowchart-like way to describe the logic: “Is somebody on gender-affirming hormone therapy [GAHT]? If yes, know what few lab tests are affected by that. If it’s based on the affirmed gender, then you generally go with that.”
November 2026—This conversation is part of a series of one-on-one virtual roundtables in which CAP TODAY publisher Bob McGonnagle speaks with one vendor and one laboratory expert to spotlight a company and a customer for their laboratory solutions and work. He spoke on Aug. 6 with Emmanuel Gorospe, MD, MPH, GI medical director for Castle Biosciences, and Daniel Jondle, MD, gastrointestinal pathologist and director of the Arizona Digestive Health pathology laboratory. Dr. Jondle is a paid speaker of Castle and was compensated for his participation in this roundtable session.
November 2026—I had the pleasure last month of hosting the first-ever Global Community Reception at our CAP26 annual meeting in Las Vegas. It was a gathering of pathology leaders from outside the United States as well as senior leadership members from the CAP.
Interactive Product Guides
Use our comprehensive guides to view and compare instruments and software systems feature by feature.
FEATURED GUIDE: LIS
November 2026—The laboratory can be seen as the diagnostic ecosystem for the entire enterprise. As such, the laboratory information system, or LIS, is the CNS, or central nervous system, said Liron Pantanowitz, MD, PhD, MHA, of UPMC/University of Pittsburgh. “It’s the digital backbone to everything.”
MARKETPLACE
February 2025—Mainz Biomed announced an agreement with Quest Diagnostics to support commercialization of Mainz Biomed’s next-generation screening test for colorectal cancer, ColoAlert. Quest will provide clinical trial laboratory services for Mainz Biomed’s ReconAAsense study, a prospective clinical study that will include approximately 15,000 subjects from 150 sites across the United States to develop data supporting FDA validation of the test. Mainz Biomed will provide Quest with the option to exercise semi-exclusive rights to provide testing services based on the test kit for an 18-month period, assuming the test’s approval by the FDA.